[go: up one dir, main page]

TWI367112B - Immediate-release tablet formulations of a thrombin receptor antagonist - Google Patents

Immediate-release tablet formulations of a thrombin receptor antagonist

Info

Publication number
TWI367112B
TWI367112B TW096123547A TW96123547A TWI367112B TW I367112 B TWI367112 B TW I367112B TW 096123547 A TW096123547 A TW 096123547A TW 96123547 A TW96123547 A TW 96123547A TW I367112 B TWI367112 B TW I367112B
Authority
TW
Taiwan
Prior art keywords
immediate
receptor antagonist
release tablet
tablet formulations
thrombin receptor
Prior art date
Application number
TW096123547A
Other languages
English (en)
Other versions
TW200810792A (en
Inventor
Rajan Gupta
Suliman Chawdry
Srinivas S Duggirala
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of TW200810792A publication Critical patent/TW200810792A/zh
Application granted granted Critical
Publication of TWI367112B publication Critical patent/TWI367112B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW096123547A 2006-06-30 2007-06-28 Immediate-release tablet formulations of a thrombin receptor antagonist TWI367112B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81782106P 2006-06-30 2006-06-30

Publications (2)

Publication Number Publication Date
TW200810792A TW200810792A (en) 2008-03-01
TWI367112B true TWI367112B (en) 2012-07-01

Family

ID=38895141

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096123547A TWI367112B (en) 2006-06-30 2007-06-28 Immediate-release tablet formulations of a thrombin receptor antagonist

Country Status (18)

Country Link
US (2) US20080031943A1 (zh)
EP (2) EP2491922B1 (zh)
JP (2) JP5116764B2 (zh)
KR (1) KR20090023670A (zh)
CN (2) CN104922054A (zh)
AR (1) AR061790A1 (zh)
AU (1) AU2007269733B2 (zh)
BR (1) BRPI0713935A2 (zh)
CA (1) CA2656395C (zh)
CL (1) CL2007001923A1 (zh)
CO (1) CO6150126A2 (zh)
ES (2) ES2616405T3 (zh)
MX (1) MX2009000131A (zh)
NO (1) NO20090467L (zh)
PE (1) PE20080376A1 (zh)
TW (1) TWI367112B (zh)
WO (1) WO2008005353A2 (zh)
ZA (1) ZA200900350B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
WO2008079260A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
US8624050B2 (en) * 2007-06-22 2014-01-07 General Electric Company Solution process for transparent conductive oxide coatings
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
DK2438060T3 (da) 2009-06-04 2014-01-13 Merck Sharp & Dohme Aktiv metabolit af en trombin-receptor-antagonist
CA2764172A1 (en) * 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
CN102442965B (zh) * 2010-09-30 2013-12-11 天津药物研究院 用于治疗血栓性疾病的par-1拮抗剂及其制备方法和用途
WO2017134200A1 (en) 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
MX2020008137A (es) * 2018-02-02 2020-10-19 Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro Formulaciones orales y usos de las mismas.
JP7482925B2 (ja) 2022-03-29 2024-05-14 ダイハツ工業株式会社 部品生産ライン

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61137813A (ja) * 1984-12-07 1986-06-25 Sawai Seiyaku Kk 持続性セフラジン製剤
JPS63162620A (ja) * 1986-12-25 1988-07-06 Teisan Seiyaku Kk 遅溶性顆粒及びそれを用いた持続性複合顆粒
GB9414045D0 (en) * 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
US20010003588A1 (en) * 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
JPH10130142A (ja) * 1996-10-31 1998-05-19 Zensei Yakuhin Kogyo Kk 放出持続型圧縮製剤
JPH10298062A (ja) * 1997-04-24 1998-11-10 Pfizer Pharmaceut Co Ltd 口腔内速溶型錠剤
ZA9810685B (en) * 1997-11-25 1999-12-23 Schering Corp Thrombin receptor antagonists.
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US6630451B1 (en) 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
WO2001000656A2 (en) 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
MXPA02012447A (es) * 2000-06-15 2003-04-25 Schering Corp Antagonistas receptores de trombina.
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
WO2002068425A1 (en) * 2001-02-23 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
CN100402499C (zh) 2001-04-19 2008-07-16 卫材R&D管理有限公司 2-亚氨基吡咯烷衍生物
NZ531869A (en) 2001-10-18 2006-11-30 Schering Corp Himbacine analogues as thrombin receptor antagonists
SG164279A1 (en) * 2002-04-16 2010-09-29 Schering Corp Tricyclic thrombin receptor antagonists
DE10317816A1 (de) 2003-04-16 2004-11-04 Claas Selbstfahrende Erntemaschinen Gmbh Feldhäcksler mit positionierbarer Fahrerkabine
CZ300438B6 (cs) * 2003-11-25 2009-05-20 Pliva Hrvatska D.O.O. Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
CN101384259A (zh) * 2005-12-22 2009-03-11 先灵公司 作为预防来自心肺外科手术的并发症的凝血酶受体拮抗剂
TW200812619A (en) * 2006-04-06 2008-03-16 Schering Corp TRA combination therapies
JP2009542677A (ja) * 2006-06-30 2009-12-03 シェーリング コーポレイション トロンビン受容体拮抗薬の固形製剤
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
WO2008079260A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
AU2008230116A1 (en) * 2007-03-23 2008-10-02 Schering Corporation Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist

Also Published As

Publication number Publication date
MX2009000131A (es) 2009-01-26
ZA200900350B (en) 2010-01-27
WO2008005353A2 (en) 2008-01-10
CO6150126A2 (es) 2010-04-20
WO2008005353A3 (en) 2008-06-26
AU2007269733A1 (en) 2008-01-10
EP2034969A2 (en) 2009-03-18
KR20090023670A (ko) 2009-03-05
ES2616354T3 (es) 2017-06-12
EP2034969B1 (en) 2017-01-11
US20170224666A9 (en) 2017-08-10
TW200810792A (en) 2008-03-01
CA2656395A1 (en) 2008-01-10
AU2007269733B2 (en) 2013-02-21
US20080031943A1 (en) 2008-02-07
JP2009542678A (ja) 2009-12-03
AR061790A1 (es) 2008-09-24
JP5116764B2 (ja) 2013-01-09
PE20080376A1 (es) 2008-06-13
EP2491922B1 (en) 2017-01-04
NO20090467L (no) 2009-03-19
CN101511345A (zh) 2009-08-19
JP2012126752A (ja) 2012-07-05
CN104922054A (zh) 2015-09-23
EP2491922A1 (en) 2012-08-29
CL2007001923A1 (es) 2008-02-08
US20160193196A1 (en) 2016-07-07
BRPI0713935A2 (pt) 2012-12-04
CA2656395C (en) 2016-12-13
ES2616405T3 (es) 2017-06-13

Similar Documents

Publication Publication Date Title
TWI367112B (en) Immediate-release tablet formulations of a thrombin receptor antagonist
HUS2100003I1 (hu) Angiotenzin receptor antagonista és NEP inhibitor gyógyszerészeti kombinációja
HUS2400046I1 (hu) Specifikus endotelin receptor antagonistát és PDE5-inhibitort tartalmazó terápiás készítmények
IL198869A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A PDGFRa ANTAGONIST
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
SI2079688T1 (sl) Spojine glukagon receptorskih antagonistov, sestavki vsebujoči take spojine in njihova farmacevtska raba
EP1945197A4 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS COMPRISING A BETA ADRENE RECEPTOR ANTAGONIST WITH EXTENDED RELEASE
PL2343071T3 (pl) Farmaceutyczne postacie dawkowania
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
IL194355A0 (en) Orally disintegrating tablets
EP2133096A4 (en) IN THE MOUTHING TABLET
HK1121970A1 (en) Sustained release pharmaceutical formulation comprising phenylephrine
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
EP2114381A4 (en) ORAL TRIPLE CONTINUOUS RELEASE TABLET
IL204528A (en) Pharmaceutical dosage forms for immediate sustained release of metadoxin
IL198780A0 (en) Pharmaceutical formulation comprising neurokinin antagonist
EP2191830A4 (en) SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
HK1129577A1 (en) Bilayer tablet for preventing cardiovascular events
ZA200902592B (en) Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
HK1135110A1 (en) Nk1 receptor antagonist composition nk1
SI2040684T1 (sl) Večenotne tablete
EP2211843B8 (en) Pharmaceutical moire pill
EP2211847A4 (en) PHARMACEUTICAL FORMULATION WITH CONTROLLED RELEASE
GB2458593C2 (en) Anthelmintic tablet formulations
GB0605104D0 (en) Tablet dispenser

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees